27-02-2013

4SC AG announced that its fully-owned research subsidiary 4SC Discovery GmbH has entered into an exclusive research and license agreement with LEO Pharma A/S, Ballerup, Denmark with the primary aim of jointly researching, developing and commercialising an oral treatment for inflammatory skin ...

more

27-02-2013

Researchers from the Department of Life Sciences and the National Institute for Biotechnology in the Negev at Ben-Gurion University of the Negev in collaboration with Teva pharmaceutical industries LTD. have engineered a natural immune system receptor into a promising drug candidate for the ...

more

Ponesimod to proceed to Phase III clinical development in psoriasis

21-12-2012

Actelion announced that its selective S1P1 modulator, ponesimod, successfully met the primary endpoint - the proportion of patients with at least 75% improvement in Psoriasis Area and Severity Index (PASI) from baseline (PASI75) at week 16 - in a double blind, placebo-controlled study ...

more

Oral Vascular Adhesion Protein-1 antagonist for the treatment of inflammation in rheumatoid arthritis and psoriasis

02-03-2012

Proximagen Group plc announced that it had commenced dosing in a Phase I clinical trial of PRX167700, a Vascular Adhesion Protein-1 (VAP-1) antagonist, for the treatment of inflammation in rheumatoid arthritis (RA) and psoriasis.Proximagen’s PRX167700 is an oral drug candidate that is ...

more

05-10-2011

Creabilis SA has raised €15 million ($20 million) in a Series B funding round led by Abbott Biotech Ventures. Existing investors Neomed and Sofinnova Partners, as well as private Italian investors, joined the round. The new funds will be used to finance the development of the company’s ...

more

BT-061 in clinical development for the treatment of RA and psoriasis

24-06-2011

Abbott and Biotest AG announced a global agreement to develop and commercialize BT-061, a novel anti-CD4 antibody for the treatment of rheumatoid arthritis (RA) and psoriasis. BT-061 is currently in Phase II clinical trials for RA and psoriasis, with preclinical studies underway to study its ...

more

Two disease-modifying antirheumatic drugs, TNF inhibitors and hydroxychloroquine, are associated with a reduced risk for the development of diabetes in psoriasis and rheumatoid arthritis patients

23-06-2011

Individuals with systemic inflammatory conditions, such as rheumatoid arthritis (RA) and psoriasis, experience a 1.5 to 2-fold increased rate of cardiovascular disease. Previous research suggests that inflammation and insulin resistance, linked with these conditions, likely accelerate the ...

more

14-03-2011

Creabilis SA announced positive results from its Phase IIa study of its lead product CT327 in psoriasis vulgaris. CT327 is a novel topically applied TrkA kinase inhibitor developed using Creabilis’ LSE (Low Systemic Exposure) technology. LSE technology creates new chemical entities with ideal ...

more

08-03-2011

AstraZeneca and Galderma Pharma S.A. announced they have entered into a R&D collaboration to develop new treatments for dermatological conditions including psoriasis, acne and atopic dermatitis which significantly affect the health and quality of life for millions ...

more

24-02-2011

Immune systems have their sinister side, especially when they have not learned how hard to fight. Crohn's disease and other inflammatory bowel diseases inflict more than a million Americans with debilitating pain and digestive unrest because of uncontrolled immune responses in the gut.How ...

more